Many Medicaid enrollees with kind 2 diabetes have restricted entry to cardioprotective medicines, together with sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), in accordance with a research printed on-line April 22 within the Annals of Inner Drugs.
Utilizing dipeptidyl peptidase-4 inhibitors (DPP4is) as a benchmark, Anil N. Makam, M.D., from UCSF at San Francisco Common Hospital, and colleagues examined the unrestricted availability of SGLT2is and GLP-1 RAs. All 50 state Medicaid fee-for-service (FFS) plans and 273 nonelderly grownup managed care group (MCO) plans with complete protection in March 2024 had been included within the research.
The researchers discovered that 80% of fifty FFS plans had unrestricted availability of SGLT2is, 60% had unrestricted availability of GLP-1 RAs, 82% had unrestricted availability of both, 58% had unrestricted availability of each, and 84% had unrestricted availability of DPP4is. General, 67% of MCO plans had availability of SGLT2is, 48% had availability of GLP-1 RAs, 67% had availability of both, 47% had availability of each, and 75% had availability of DPP4is. There was marked variation noticed amongst states within the proportion of MCO enrollees with availability (SGLT2i vary, 24 to 100%; GLP-1 RA vary, 0 to 99%; DPP4i vary, 41 to 100%). Restricted availability was seen in 25%, 40%, and 22% of enrollees for SGLT2is, GLP-1 RAs, and DPP4is, respectively, primarily on account of extra MCO restrictions. From 2020 to 2024, availability elevated, particularly in FFS; GLP-1 RA availability in MCOs plateaued at lower than 60% since 2022. Tirzepatide was nearly completely restricted.
“Formulary plan coverage is a potential lever to mitigate health inequities for low-income Medicaid enrollees with diabetes,” the authors write.
Extra info:
Availability of Cardioprotective Medicines for Kind 2 Diabetes within the Medicaid Program, Annals of Inner Drugs (2025). DOI: 10.7326/ANNALS-24-01449 www.acpjournals.org/doi/10.7326/ANNALS-24-01449
Quotation:
Many Medicaid enrollees have restricted entry to SGLT2 inhibitors, GLP-1 receptor agonists (2025, April 30)
retrieved 1 Could 2025
from https://medicalxpress.com/information/2025-04-medicaid-enrollees-restricted-access-sglt2.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
